Vericel (VCEL)
Markets patient-specific cell therapies for knee-cartilage repair and severe burns, plus enzymatic burn debridement.
Something off on this page? Send us feedback.
Sells patient-specific MACI implants for knee-cartilage repair, Epicel skin grafts for extensive burns, and NexoBrid for enzymatic burn debridement in the United States. Most revenue comes from MACI, while commercialization depends on regulated manufacturing, specialist adoption, reimbursement, and MediWound’s supply of NexoBrid.
Manufactures and markets three FDA-approved advanced therapies for sports medicine and severe burn care in the United States. MACI turns a patient’s knee-cartilage biopsy into a cellular implant and offers instruments for arthroscopic delivery. Epicel creates permanent skin-replacement grafts for extensive burns, while NexoBrid uses enzymes to remove burn eschar.
Handles patient-specific cell manufacturing and sells through orthopedic, hospital, burn-center, and specialty-distributor channels within one reportable segment. MACI and Epicel depend on FDA-regulated production and specialist adoption; MACI manufacturing is shifting to the Burlington facility. NexoBrid relies on licensed North American rights and supply from MediWound’s Israeli operations. Revenue remains concentrated in MACI and the U.S. market.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 30, 2026 | Canaccord Genuity | Target | Target: — | Target: $60 |
| Jul 16, 2026 | Truist Financial | Target | Target: $42 | Target: $54 |
| May 8, 2026 | H.C. Wainwright | Target | Target: $60 | Target: $70 |
| Apr 15, 2026 | Truist Financial | Target | Target: $45 | Target: $42 |
| Mar 10, 2026 | Leerink Partners | Target | Target: — | Target: $46 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $162.5M · Total debt $92.5M · Total assets $502.9M · Shareholders' equity $370.0M
- Revenue
- $77.5M
- Operating income
- $434.0K
- Net income
- $2.2M
No dividends on record.
| Institutions | ≈ 107.70% | 55.15M shares | |
|---|---|---|---|
| 325 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.22% | 622.9K shares | |
| 14 holders · as of Aug 14, 2026 | |||
| Strategic holders | 6.26% | 3.20M shares | |
| 1 holder · as of Feb 14, 2022 | |||
| Adds to | 115.18% | ||
51.21M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.18%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.80% | 8.09M | as of Jun 30, 2026 |
State Street CorpInstitution | 6.43% | 3.29M | as of Jun 30, 2026 |
Alger Associates, Inc.Strategic | 6.26% | 3.20M | filed Feb 14, 2022 |
Congress Asset Management Co /MAInstitution | 5.70% | 2.92M | as of Jun 30, 2026 |
Soleus Capital Master Fund, L.P.Institution | 4.98% | 2.55M | filed Apr 1, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Kevin F. Mclaughlin | director | −7,000 | $44.53 |
| Aug 3, 2026 | Michael Halpin | officer: Chief Operating Officer | −10,000 | $46.84 |
| Jul 30, 2026 | Jonathan Siegal | officer: Principal Accounting Officer | −500 | $48.90 |
| Jun 26, 2026 | Sean C. Flynn | officer: Chief Legal Officer | −15,000 | $45.64 |
| Jun 26, 2026 | Jonathan Mark Hopper | officer: Chief Medical Officer | −5,000 | $45.00 |
- Smith & Nephew (ADR)
Broad sports-medicine and burn-wound medtech overlap
- Zimmer Biomet
Juvenile cartilage allograft alternative to MACI
- Stryker
Cartilage allograft and sports-medicine channel substitute
- AVITA Medical
Autologous skin-cell burn-care alternative
- Integra LifeSciences
Dermal regeneration template for severe burn coverage
- Organogenesis
Regenerative wound-care and skin-substitute peer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vericel | $40.10 | +1.40% | $2.03B | 84.5 | 59.9 | 6.6 | +22.5% |
| Smith & Nephew (ADR) | $27.54 | −0.56% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Zimmer Biomet | $93.98 | −0.36% | $18.25B | 22.9 | 10.7 | 2.1 | +4.8% |
| Stryker | $275.98 | +0.65% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| AVITA Medical | $11.50 | +6.09% | $269.3M | — | — | 3.6 | +78.6% |
| Integra LifeSciences | $15.99 | +2.53% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Organogenesis | $1.48 | +5.71% | $180.1M | — | — | 0.4 | −56.7% |
| Median | 22.9 | 10.7 | 2.0 | +4.7% |